

# TEACHING STAFF

Agustín Albillos. Department of Gastroenterology and Hepatology, Ramón y Cajal University Hospital, Ramón y Cajal Research Institute (IRYCIS), CIBERehd, University of Alcalá, Madrid, Spain

Antonio Pérez Pérez. Endocrinology and Nutrition Department, Santa Creu i Sant Pau Hospital, Spanish Diabetes Society (SED), Spain.

Eva Pérez Bech. National Federation of Liver Patients and Transplant Recipients (FNETH), Spain.

Graciela Castro Narro. Department of Gastroenterology. National Institute of Medical Sciences and Nutrition Salvador Zubirán. México City, México

Javier Crespo. Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

Jeffrey Lazarus. Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

Jörn M. Schattenberg. Metabolic Liver Research Program, Department of Medicine, University Medical Centre Mainz, Mainz, Germany.

John F. Dillon. Department of Molecular and Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, United Kingdom.

Jose Luis Calleja. Department of Gastroenterology and Hepatology, Puerta de Hierro University Hospital, Puerta de Hierro Health Research Institute (IDIPHIM), CIBERehd, Majadahonda, Spain

Juan Basterra. CEO Mikrobiomik, Derio, Bizkaia, Spain.

Kenneth Cusi. Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, Veterans Health Administration and University of Florida, Gainesville, FL, USA.

Marco Arrese. Department of Gastroenterology, Pontifical Catholic University of Chile, Santiago, Chile.

María Luz Martínez Chantar. Liver Disease Lab, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Bizkaia, Spain.

María Teresa Arias Loste. Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

Mary E Rinella. Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Manuel Romero. UCM Digestive Diseases and CIBERehd, Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain.

Miguel Mateo. General Subdirector of Pharmacy Organisation and Inspection in the Government of Cantabria, Santander, Spain.

Paula Iruzubieta. Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

Ramon Bataller. Center for Liver Diseases, Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, PA, USA.

Salvador Augustin. Senior Clinical Program Leader - NASH · Boehringer Ingelheim International, Germany.

Shira Zelber-Sagi. University of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health, Mount Carmel, Haifa, Israel. Department of Gastroenterology, Tel- Aviv Medical Centre, Tel- Aviv, Israel.

Tatiana Fernández Lanás. Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain. Valdecilla, IDIVAL, Santander, Spain.

# IDIVAL Precision Medicine FORUM

## NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) UPDATED (EN)

From 9 to 18 May  
Virtual attendance



[www.idival.org](http://www.idival.org)

Con el aval de:



Course length: 17.5 hours  
Dates: from 9 to 18 May 2022  
Timetable: Monday to Wednesday  
Where: virtual attendance  
Inscriptions: [www.idival.org](http://www.idival.org)

### COURSE COORDINATORS

**Dr. Javier Crespo**

Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

**Dr. Jeffrey Lazarus**

Barcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.

**Dra. Paula Iruzubieta**

Gastroenterology and Hepatology Unit, Marqués de Valdecilla University Hospital, IDIVAL, Santander, Spain.

### Teacher coordinator

**Natalia Puente Fernández**

Project Manager, Superior Technician, IDIVAL.

### AIMS

Liver disease is one of the leading causes of lost years of working life in Europe, second only to ischaemic heart disease. And, without a doubt, non-alcoholic fatty liver disease (NAFLD) is the most frequent cause of chronic liver disease in our environment. Progress in the prevention and treatment of NAFLD is closely linked to the understanding of this disease from the pathophysiological and clinical point of view as a basis for a better definition of risk factors, the establishment of adequate predictors of disease progression, the definition of new biomarkers and the individualisation of therapy adjusted to the characteristics of each patient.

### TARGET GROUP

The programme is aimed at clinical, research, and support staff with an interest in the field of the speciality, who wish to learn more about aspects related to research and precision medicine from experts.

# COURSE PROGRAMME

## MODULE 1. May 9, 2022

Concept, epidemiology and burden of the disease.

16:00-16:45

NAFLD. A global vision of the disease.  
Javier Crespo.

16:45-17:30

Disease burden and economic impact of NAFLD.

Jeffrey Lazarus.

17:30-18:15

The recognition of hidden chronic liver disease as a silent epidemic.

Marco Arrese.

18:15-19:00

The experience of one of the countries with the highest prevalence of NAFLD: Mexico.

Graciela Castro Narro.

## MODULE 2. May 10, 2022

Pathogenesis of NAFLD and Diagnostic approaches to the NAFLD.

16:00-16:45

From the laboratory bench to the patient's bedside.

Paula Iruzubieta.

16:45-17:30

Magnesium metabolism in NAFLD.  
María Luz Martínez Chantar.

17:30-18:15

Screening for NAFLD: To whom, where and how.

JM Schattenberg.

18:15-19:00

Diagnosis and management of NAFLD in Diabetes Clinics.

Antonio Pérez Pérez.

## MODULE 3. May 11, 2022

Clinical trials in NAFLD.

16:00-16:45

Endpoints in NAFLD, are we sure?

Mary E Rinella.

16:45-17:30

Current challenges in NAFLD clinical trials.

John F. Dillon.

17:30-18:15

Endoscopic treatment of NASH. Reality or fiction?

Jose Luis Calleja.

18:15-19:00

Fecal microbiota transplantation.

Javier Crespo.

## MODULE 4. May 16, 2022

Another vision is possible.

16:00-16:45

A startup company that wants to transplant microbiota.

Juan Basterra.

16:45-17:30

A large company that wants to go to the roots of the problem.

Salvador Augustin.

17:30-18:15

Multidisciplinary collaborative care in the management of NAFLD patients.

Kenneth Cusi.

18:15-19:00

The invisible hands in NAFLD clinical research.  
Tatiana Fernández Lanás.

## MODULE 5. May 17, 2022

The essential commitment and education of patients in this disease.

16:00-16:45

The role of nutrition in NAFLD.

Manuel Romero.

16:45-17:30

Influence of alcohol on NAFLD: How can we measure it?

Ramon Bataller.

17:30-18:15

A patient guideline (and the non-expert physician).

Shira Zelber-Sagi.

18:15-19:00

The main actors of this disease

Eva Pérez Bech.

Agustín Albillos.

## MODULE 6. May 18, 2022

Disease as a public health opportunity.

16:00-16:45

Collaborative research. HEPAmet Registry: an extremely useful tool for research.

Maria Teresa Arias Loste.

16:45-17:30

Telemedicine in NAFLD.

Miguel Mateo.

17:30-18:15

The consensus on "Advancing the global public health agenda for NAFLD".

Jeffrey Lazarus.

18:15-18:30

Concluding remarks.

Javier Crespo.

Jeffrey Lazarus.

Paula Iruzubieta.

[www.idival.org](http://www.idival.org)



@IDIVALdecilla



/IDIVALInstitutodelInvestigación